Faruqi & Faruqi Highlights REGENXBIO Class Action Deadline Approaching in 2026

Faruqi & Faruqi Highlights Critical Deadline for REGENXBIO Investors

Faruqi & Faruqi, LLP, a nationally recognized securities law firm, is actively investigating claims against REGENXBIO Inc. (NASDAQ: RGNX) and is reminding investors of a significant deadline pertaining to a federal securities class action against the company. This deadline is set for April 14, 2026. The firm encourages investors who experienced losses in REGENXBIO between February 9, 2022, and January 27, 2026, to reach out and discuss their legal rights and options.

The context behind this investigation stems from allegations that REGENXBIO and its executives may have violated federal securities laws. This concerns claims of making misleading statements regarding the efficacy and safety of their investigational gene therapies, particularly the RGX-111 trial. As per the latest updates, on January 28, 2026, the U.S. Food and Drug Administration (FDA) issued a clinical hold on RGX-111. This decision came following the observation of a serious adverse event, which included a participant developing a neoplasm during the Phase I/II trials.

Additionally, the FDA also imposed a clinical hold on RGX-121, which is aimed at treating Hunter syndrome, due to the products sharing study populations and risking safety outcomes. The exposure of these adverse events led to a significant decline in REGENXBIO’s stock price, plummeting by almost 18%—a concern for investors who were unaware of these substantial risks at the time.

The implications of the class action are that by filing, investors can be represented collectively in legal proceedings. The lead plaintiff, who will be the individual with the most significant financial stake, plays an important role in guiding the litigation for the class. Investors can choose to participate actively as lead plaintiffs or may remain passive members of the class. Their decision will not sway their potential recovery if the case is successful.

Faruqi & Faruqi welcomes any former employees, shareholders, or whistleblowers who might possess relevant information about REGENXBIO’s conduct to contact the firm. The firm has a proven track record, having recovered substantial sums for investors and firmly stands ready to advocate on their behalf.

For those affected, or who believe they may have a claim, reaching out to the firm is highly encouraged. Investors can obtain more detailed information regarding the class action at Faruqi & Faruqi's official website: www.faruqilaw.com/RGNX. They may also contact Faruqi & Faruqi partner, Josh Wilson, directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

In these turbulent financial times, it is crucial for investors to be vigilant about their rights and options. The approaching deadline serves as a reminder for those who have suffered losses to take timely action. Faruqi & Faruqi, LLP remains committed to serving the best interests of investors affected by potentially misleading actions of companies in the securities markets.

Stay informed and updated by following the firm’s announcements on LinkedIn, X (formerly Twitter), or Facebook. The class action lawsuit could be a significant step towards accountability and financial recovery for shareholders of REGENXBIO as the situation unfolds.